Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S. Tauro S, et al. Among authors: jackson g. J Clin Oncol. 2005 Dec 20;23(36):9387-93. doi: 10.1200/JCO.2005.02.0057. Epub 2005 Nov 28. J Clin Oncol. 2005. PMID: 16314618 Clinical Trial.
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
Jackson GH, Angus B, Carey PJ, Finney RD, Galloway MJ, Goff DK, Haynes A, Lennard AL, Leonard RC, McQuaker IG, Proctor SJ, Russell N, Windebank K, Taylor PR; Scotland and Newcastle Lymphoma Group. Jackson GH, et al. Leuk Lymphoma. 2000 May;37(5-6):561-70. doi: 10.3109/10428190009058508. Leuk Lymphoma. 2000. PMID: 11042516 Clinical Trial.
Skin explant model of human graft-versus-host disease: prediction of clinical outcome and correlation with biological risk factors.
Wang XN, Collin M, Sviland L, Marshall S, Jackson G, Schulz U, Holler E, Karrer S, Greinix H, Elahi F, Hromadnikova I, Dickinson AM. Wang XN, et al. Among authors: jackson g. Biol Blood Marrow Transplant. 2006 Feb;12(2):152-9. doi: 10.1016/j.bbmt.2005.09.018. Biol Blood Marrow Transplant. 2006. PMID: 16443513 Free article. Clinical Trial.
The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis.
Cook G, Jackson GH, Morgan GJ, Russell N, Kirkland K, Lee J, Pearce R, Marks DI, Pagliuca A; British Society for Blood and Marrow Transplantation (BSBMT). Cook G, et al. Among authors: jackson gh. Bone Marrow Transplant. 2011 Sep;46(9):1210-8. doi: 10.1038/bmt.2010.283. Epub 2010 Nov 22. Bone Marrow Transplant. 2011. PMID: 21102497
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. Morgan GJ, et al. Among authors: jackson gh. Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3. Lancet. 2010. PMID: 21131037 Free PMC article. Clinical Trial.
3,121 results